Market research
LVTX LAVA Therapeutics NV
NASDAQ USD Healthcare
Latest close
As of 26 Dec 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 46M
- P/E ratio
- Not available
- Analyst target
- 1.5154
- Dividend yield
- Not available
- Beta
- 0.5
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- NL0015000AG6
- Market cap
- 46M
- P/E ratio
- Not available
- Analyst target
- 1.5154
- Dividend yield
- Not available
- Beta
- 0.5
About
About LAVA Therapeutics NV
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. The company has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is based in Utrecht, the Netherlands.
Research context
LAVA Therapeutics NV appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the LVTX discussion.
5 years, 7 months ago
From a valuation standpoint, the stock is 94.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 77.4.
Based on the above factors, Lava Therapeutics B.V gets an overall score of 1/5.